Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07414134 · ClinicalTrials.gov registry record
Exacerbations and Real-World Outcomes Among Patients With Chronic Obstructive Pulmonary Disease Following Severe Exacerbation
A clinical trial of Chronic Obstructive Pulmonary Disease, sponsored by AstraZeneca.
- Completed
- Registry status
- 3,598
- Enrollment target
- 1
- Study location
NCT07414134 is a study of Chronic Obstructive Pulmonary Disease that has completed, run by AstraZeneca. The registered enrollment target is 3,598 participants, above the 1,712-participant average among 86 other Chronic Obstructive Pulmonary Disease trials with a reported enrollment target (110% higher). The trial reports 1 study location across 1 state.
The verdict
NCT07414134, a study of Chronic Obstructive Pulmonary Disease, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- 3,598 participants
- Enrollment target
- 1
- Study location
Study Summary
This real-world retrospective study will use de-identified administrative claims data and will examine patients with a diagnosis of COPD who have experienced a qualifying severe disease exacerbation and received subsequent treatment with BGF. Agreed COPD patient data from the Inovalon MORE2 Registry® and Centers for Medicare \& Medicaid Services (CMS) 100% Medicare Fee for Service (FFS) database spanning from January 1, 2021 to the most recently available data (September 30th, 2024 for the MORE2 database, and December 31st, 2023 for the Medicare FFS database) will be used for this analysis. All patients will be required to present at least one prescription claim for BGF. Patients will also be required to show evidence of a qualifying severe COPD exacerbation event during the 180-day period preceding initiation of BGF. Index date will be set as the date of discharge from the qualifying severe exacerbation event.
Conditions Studied
Interventions
- DRUG BGF- BUDESONIDE/GLYCOPYRRONIUM/FORMOTEROL
Study Locations (1)
Maryland
- AstraZeneca - Gaithersburg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,598 participants |
| Start Date | 2025-10-31 |
| Est. Completion | 2025-11-28 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07414134
The ClinicalTrials.gov registry entry for NCT07414134 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 3,598 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 1,712-participant average among 86 other Chronic Obstructive Pulmonary Disease trials with a reported enrollment target (110% higher). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Chronic Obstructive Pulmonary Disease appearing as the primary indexed condition, and to 1 intervention - of which BGF- BUDESONIDE/GLYCOPYRRONIUM/FORMOTEROL is the first listed.
NCT07414134 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT07414134 about?
NCT07414134 is a clinical study titled "Exacerbations and Real-World Outcomes Among Patients With Chronic Obstructive Pulmonary Disease Following Severe Exacerbation". This real-world retrospective study will use de-identified administrative claims data and will examine patients with a diagnosis of COPD who have experienced a qualifying severe disease exacerbation and received subsequent treatment with BGF. Agreed COPD patient data from the Inovalon MORE2 Registry...
What is the current status of trial NCT07414134?
This trial is currently completed. The enrollment target is 3,598 participants. The study started on 2025-10-31. Estimated completion is 2025-11-28.
What conditions does trial NCT07414134 study?
This clinical trial studies the following conditions: Chronic Obstructive Pulmonary Disease.
What interventions are being tested in trial NCT07414134?
The interventions under investigation include: BGF- BUDESONIDE/GLYCOPYRRONIUM/FORMOTEROL (DRUG).
Who is sponsoring clinical trial NCT07414134?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07414134 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Obstructive Pulmonary Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Mindful Steps 2.0: Promoting Physical Activity in Patients With COPD and HF
RECRUITING · NA
-
Boston Early-Onset Chronic Obstructive Pulmonary Disease (COPD) Study
RECRUITING
-
Evaluating the Safety and Efficacy of dNerva Lung Denervation System in Patients With COPD
RECRUITING · NA
-
A Study to Assess the Efficacy and Safety of Verekitug in Participants With COPD
RECRUITING · Phase 2
-
The Cardiovascular Consequences of Sleep Apnea Plus COPD (Overlap Syndrome)
RECRUITING · Phase 2
-
COPD Care Pathway Among Patients With Cancer
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.